Shenzhen Hepalink Pharma Enters $441 Million Deal for Resverlogix CV Drug

Shenzhen Hepalink Pharma, a major global supplier of heparin API, signed a framework agreement to acquire greater China rights for a novel BET inhibitor from Resverlogix of Canada. The deal includes an investment in Resverlogix of $41 million and a package of milestones and sales royalties that could top $400 million. Resverlogix is planning a global Phase III trial of the drug, RVX-208, in patients with cardiovascular disease. Earlier this month, Resverlogix secured China patent approvals for RVX-208 and said it would attend the ChinaBio® Partnering Forum to seek a China partner for the drug. More details.... Stock Symbols: (SHE: 002399) (TSX: RVX) Share this with colleagues: // //